All Posts
Review: How to ventilate obstructive and asthmatic patients
20 Nov, 2020 | 08:39h | UTCHow to ventilate obstructive and asthmatic patients – Intensive Care Medicine
Commentary on Twitter
Ventilation in #COPD & asthma
➡️ respiratory mechanics/gas exchange
➡️ heart–lung interactions
➡️ HFNO & NIV
➡️ managing invasive MV from intubation to (early) weaning limiting hyperinflation
➡️ long‑term outcome & role of tracheostomy
➡️ future strategieshttps://t.co/zBBlwo7EEI pic.twitter.com/4WPeYJZrh4— Intensive Care Medicine (@yourICM) November 9, 2020
Opinion: Improving care for heart failure with reduced ejection fraction—a potential polypill-based strategy
20 Nov, 2020 | 08:37h | UTC
Five rules for evidence communication
20 Nov, 2020 | 08:38h | UTCFive rules for evidence communication – Nature
Commentary from the author on Twitter
Today in @NatureNews with @d_spiegel & team we present “five rules for evidence communication”
1) Inform, not persuade
2) Offer balance but not false balance
3) Disclose uncertainties
4) State evidence quality
5) Inoculate against misinformationhttps://t.co/Apa1OdIeha pic.twitter.com/SdnGJzI1mK— Sander van der Linden (@Sander_vdLinden) November 18, 2020
Pfizer and BioNTech to submit Covid-19 vaccine data to FDA as full results show 95% efficacy
19 Nov, 2020 | 09:36h | UTCPfizer and BioNTech to submit Covid-19 vaccine data to FDA as full results show 95% efficacy – STAT
News release: Pfizer and Biontech conclude phase 3 study of Covid-19 vaccine candidate, meeting all primary efficacy endpoints
Commentaries: ‘Incredible milestone for science.’ Pfizer and BioNTech update their promising COVID-19 vaccine result – Science AND Pfizer: COVID-19 shot 95% effective, seeking clearance soon – Associated Press AND Expert reaction to announcement by Pfizer that they have concluded the Phase III study of their COVID-19 vaccine candidate after demonstrating 95% efficacy – Science Media Centre AND Covid vaccine: Pfizer says ‘94% effective in over-65s’ – BBC
Opinion: For billion-dollar COVID vaccines, basic government-funded science laid the groundwork
19 Nov, 2020 | 09:33h | UTC
More people are getting COVID-19 twice, suggesting immunity wanes quickly in some
19 Nov, 2020 | 09:29h | UTCMore people are getting COVID-19 twice, suggesting immunity wanes quickly in some – Science
[Preprint] Small randomized trial showed no benefit from Vitamin D3 supplementation in patients with severe Covid-19
19 Nov, 2020 | 09:26h | UTC
Temperature concerns could slow the rollout of new coronavirus vaccines
19 Nov, 2020 | 09:31h | UTCTemperature concerns could slow the rollout of new coronavirus vaccines – Science
Hospital-acquired SARS-CoV-2 infection: Lessons for public health
19 Nov, 2020 | 09:27h | UTCHospital-Acquired SARS-CoV-2 Infection: Lessons for Public Health – JAMA
Opinion: “Proposed British guidelines reject useless chronic fatigue syndrome treatments”
19 Nov, 2020 | 09:22h | UTCProposed British guidelines reject useless chronic fatigue syndrome treatments – STAT
NICE Draft Guideline: Myalgic encephalomyelitis (or 6 encephalopathy)/chronic fatigue syndrome: diagnosis and management
#AHA20 [not published yet] Randomized trial: After drug-eluting stent implantation, one-month dual antiplatelet therapy (DAPT) followed by aspirin monotherapy was noninferior to 6-12 months of DAPT
19 Nov, 2020 | 09:21h | UTCCommentary: Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT – TCTMD
NICE Guideline: Acute coronary syndromes
19 Nov, 2020 | 09:24h | UTCAcute coronary syndromes – National Institute for Health and Care Excellence
Visual summary: STEMI
Visual summary: NSTEMI/unstable angina
Visual summary: Cardiac rehabilitation and secondary prevention
Review: Fluid administration and monitoring in ARDS. Restrictive vs. liberal strategy of fluid administration, assessment of fluid responsiveness, and other topics are discussed
19 Nov, 2020 | 09:19h | UTCFluid administration and monitoring in ARDS: which management? – Intensive Care Medicine
Commentary on Twitter
Fluid administration & monitoring in #ARDS:
➡️ pathophysiology
➡️ fluid therapy
➡️ fluid balance & outcome
➡️ restrictive vs liberal strategy?
➡️ assessing responsiveness
➡️ origin of positive balance & correction
➡️ approach according to ARDS cause/timinghttps://t.co/wIt305B1Ci pic.twitter.com/54whmo7OmC— Intensive Care Medicine (@yourICM) November 12, 2020
Perspective: More people can access surgery. That’s great for them, awful for the planet
19 Nov, 2020 | 09:18h | UTCMore People Can Access Surgery. That’s Great For Them, Awful For The Planet – NPR
Original article: Climate change: challenges and opportunities to scale up surgical, obstetric, and anaesthesia care globally – The Lancet Planetary Health
Related: Effects of Surgery on A Warming Planet: Can Anesthesia Go Green? (commentaries and articles on the subject)
Lessons from Europe, where cases are rising but schools are open
18 Nov, 2020 | 09:18h | UTCLessons From Europe, Where Cases Are Rising But Schools Are Open – NPR
11th Ebola outbreak in the Democratic Republic of the Congo declared over
19 Nov, 2020 | 09:15h | UTC
Chinese Covid-19 vaccine candidate (CoronaVac) appears safe and induces an immune response in healthy volunteers in phase 1/2 clinical trial
18 Nov, 2020 | 09:19h | UTCCommentaries: Covid-19: Chinese vaccine ‘successful in mid-stage trials’ – BBC AND Expecting the unexpected with COVID-19 vaccines – The Lancet Infectious Diseases
Commentary on Twitter
NEW—Chinese #COVID19 vaccine candidate (CoronaVac) based on inactivated SARS-CoV-2 virus appears safe & induces an immune response in healthy volunteers: finding from a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial @TheLancetInfDis https://t.co/0AC0fP53dI pic.twitter.com/W3gMdqLzTG
— The Lancet (@TheLancet) November 18, 2020
Estimation of US children’s educational attainment and years of life lost associated with primary school closures during the Covid-19 pandemic
18 Nov, 2020 | 09:15h | UTC
#AHA20 – Two studies show lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with antiarrhythmic drug therapy
18 Nov, 2020 | 09:11h | UTCStudy 1: Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation – New England Journal of Medicine
Commentaries: EARLY AF and STOP AF Put Electrophysiology at a Crossroads – Medscape (free registration required) AND EARLY-AF: First-line Ablation Beats Meds for Recent Paroxysmal A-fib – TCTMD
Commentary on Twitter (thread – click for more)
NEJM published 2 RCTs of #AFib ablation vs AF drugs.
The rub was that the ablation was done EARLY in the course.
Practice had been to try drugs first then do ablation.
EARLY AF and STOP AF studied the procedure early. #AHA20 Thread and my column >>— John Mandrola, MD (@drjohnm) November 18, 2020
[Preprint] Study suggests immunity to the Coronavirus may last years
18 Nov, 2020 | 09:20h | UTCImmunological memory to SARS-CoV-2 assessed for greater than six months after infection – bioRxiv
Commentaries: Immunity to the Coronavirus May Last Years, New Data Hint – New York Times AND Could coronavirus immunity last YEARS? Study finds even survivors who had mild COVID-19 are protected for at least 8 months and their immune ‘memory’ may last MUCH longer – Daily Mail AND COVID-19: Study Suggests Durable Immune Response After SARS-CoV-2 Infection – NEJM Journal Watch
Commentary from the author on Twitter (thread – click for more)
1/ Our pre-print on immune memory to SARS-CoV-2 is out today. To our knowledge, this is the largest such study for any acute infection.
The upshot is that there is substantial immune memory after COVID-19.
Lots of stuff in this manuscript.https://t.co/lSAyZp0XiK@SetteLab
— Prof. Shane Crotty (@profshanecrotty) November 17, 2020
ATS Guideline: Home oxygen therapy for adults with chronic lung disease
18 Nov, 2020 | 09:13h | UTC
#AHA20 – Randomized trial: Among patients with recurrent pericarditis, Rilonacept was associated with lower risk of pericarditis recurrence than placebo
18 Nov, 2020 | 09:04h | UTCPhase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Rilonacept Prevents Recurrent Pericarditis: RHAPSODY – TCTMD AND Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes stuDY – RHAPSODY – American College of Cardiology AND Trial shows drug effective in 96% of patients with recurrent pericarditis – Cleveland Clinic
Commentary on Twitter
Patients with recurrent pericarditis were treated with the interleukin-1 trap rilonacept. Those who had a response were randomly assigned to receive continued rilonacept or placebo. Rilonacept led to a significantly lower risk of pericarditis recurrence than placebo. #AHA20
— NEJM (@NEJM) November 17, 2020
#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo
18 Nov, 2020 | 09:08h | UTCSotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and Recent Worsening Heart Failure. Diarrhea and severe hypoglycemia were more common with sotagliflozin than with placebo
18 Nov, 2020 | 09:06h | UTCSotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure – New England Journal of Medicine (link to abstract – $ for full-text)
The ‘Ten Commandments’ for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease
18 Nov, 2020 | 09:03h | UTCOriginal Guideline and commentary: 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease